Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

This publication has 23 references indexed in Scilit:

• Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
  Transplantation and Cellular Therapy, 2021
• Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
  Cancer Cell, 2021
• Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
  Cancer Cell, 2021
• Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
  Blood Cancer Journal, 2021
• Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
  Leukemia, 2021
• Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
  The Lancet, 2021
• Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
  Blood, 2021
• Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy
  Nature Cancer, 2021
• Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
  Blood Advances, 2021
• Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
  Blood, 2020